Clinical Trial

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated October 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-15.
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT06371157
Lead Sponsor Akeso
Conditions Hepatocellular Carcinoma
Enrollment 469 participants
Start Date 2024-08-02
Primary Completion 2025-10-25 (estimated)
Study Completion 2026-05-23 (estimated)
Updated on ClinicalTrials.gov 2025-03-12